LEXIVA Drug Patent Profile

When do Lexiva patents expire, and when can generic versions of Lexiva launch?

Lexiva is a drug marketed by Viiv Hlthcare and is included in two NDAs.

The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lexiva

A generic version of LEXIVA was approved as fosamprenavir calcium by MYLAN on April 15^th, 2016.

Summary for LEXIVA

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	1,117
Drug Prices:	Drug price information for LEXIVA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEXIVA
What excipients (inactive ingredients) are in LEXIVA?	LEXIVA excipients list
DailyMed Link:	LEXIVA at DailyMed

See drug prices for LEXIVA

Recent Clinical Trials for LEXIVA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 3
ViiV Healthcare	Phase 1
GlaxoSmithKline	Phase 1

See all LEXIVA clinical trials

Paragraph IV (Patent) Challenges for LEXIVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXIVA	Tablets	fosamprenavir calcium	700 mg	021548	1	2012-01-18

US Patents and Regulatory Information for LEXIVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	SUSPENSION;ORAL	022116-001	Jun 14, 2007		DISCN	Yes	No
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	TABLET;ORAL	021548-001	Oct 20, 2003		DISCN	Yes	No

International Patents for LEXIVA

See the table below for patents covering LEXIVA around the world.

Country	Patent Number	Title	Estimated Expiration
Turkey	200100111
Japan	4282639
Poland	342113
Japan	2005350478	PRODRUG OF ASPARTYL PROTEASE INHIBITOR
Slovakia	285311
Bulgaria	104631
Hungary	0103432

Supplementary Protection Certificates for LEXIVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0933372	324	Finland
0933372	300339	Netherlands		300339, 20180310, EXPIRES: 20190711
0933372	C00933372/01	Switzerland		PRODUCT NAME: FOSAMPRENAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56706 17.03.2005
0933372	SPC012/2008	Ireland		SPC012/2008: 20091119, EXPIRES: 20190711
0933372	91426	Luxembourg		91426, EXPIRES: 20190712
0933372	13/2008	Austria		PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
0933372	08C0015	France		PRODUCT NAME: FOSAMPRENAVIR CALCIQUE; REG. NO/DATE: EU/1/07/282/001-002 20040712

Market Dynamics and Financial Trajectory for Lexiva (fosamprenavir)

Last updated: February 20, 2026

What is Lexiva’s current market position?

Lexiva (fosamprenavir) is an HIV protease inhibitor developed by GSK. It received approval from the FDA in 2003. Its market presence has declined due to newer antiretroviral agents with improved efficacy profiles, better tolerability, and simplified dosing.

As of 2023, Lexiva is no longer a frontline therapy. It is primarily used in salvage therapy or indicated for patients with resistance to other protease inhibitors. Its market share has decreased substantially since peak sales in the mid-2000s due to the advent of drugs such as Dolutegravir and Bictegravir.

How has Lexiva’s sales evolved over time?

Year	Estimated Global Sales (USD Millions)	Notes
2005	200	Peak sales period
2010	120	Market share declines
2015	50	Usage limited to resistant cases
2020	10	Outpaced by integrase inhibitors
2023	5	Minimal market activity

Sales peaked during 2004–2008, reaching approximately $200 million annually. Post-2010, sales entered a sharp decline, aligning with the increased adoption of integrase strand transfer inhibitors (INSTIs).

What factors influence Lexiva’s market trajectory?

Patent status and exclusivity

Lexiva's original patent expired in 2012. GSK maintained market exclusivity through patent extensions and new formulations until 2012. Post-patent expiry, generic competition emerged, adding downward pressure on pricing and sales volume.

Competition from new agents

The transition from protease inhibitors to INSTIs has been decisive. Drugs like Dolutegravir, Biktarvy, and Bictegravir demonstrate higher tolerability, fewer drug-drug interactions, and once-daily dosing, rendering Lexiva comparatively obsolete.

Formulation and dosing complexities

Lexiva requires twice-daily dosing and is associated with side effects like gastrointestinal discomfort, limiting its uptake. Newer drugs offer once-daily regimens with improved safety profiles.

Pricing strategies

Pricing for Lexiva declined alongside patent expiration, impacting revenue. Generic versions sell at significantly reduced prices, decreasing GSK’s margins.

What is the future outlook for Lexiva?

The drug is classified as an orphan molecule outside niche indications. Sales are expected to remain minimal due to low demand, limited clinical utility, and competition. Potential revival hinges on new combination therapies or new indications; however, current trends favor newer agents.

GSK has limited investment in Lexiva development. Any future licensing or reformulation appears improbable considering market trends.

How does Lexiva compare financially to competitors?

Aspect	Lexiva	Competitors (e.g., Dolutegravir)
Peak sales (2008)	~$200 million	N/A
Current sales (2023)	~$5 million	N/A
Patent status	Expired (2012)	Still under patent protection (Duttregravir: 2032)
Dosing regimen	Twice daily	Once daily
Tolerability	Moderate	High

Competitive products command higher market shares owing to superior efficacy, tolerability, and dosing convenience.

Key takeaways

• Lexiva experienced peak sales in 2005 with approximately $200 million globally.
• Its market share declined sharply post-2010, correlating with patent expiration and the rise of newer agents.
• The drug's use is now confined mainly to resistant HIV cases or salvage therapy.
• Competition from INSTIs and generic versions has rendered Lexiva commercially marginal.
• Future sales are unlikely to increase absent new formulations or indications.

FAQs

1. Why did Lexiva sales decline so rapidly?
Patent expiration, competition from newer antiretrovirals with better safety profiles, and dosing complexity contributed to its sales decline.

2. Are there any ongoing clinical trials for Lexiva?
No significant Phase III or pivotal trials are underway. The focus has shifted to new agents.

3. Can Lexiva be combined with other drugs to improve its marketability?
While combinations are possible, current standards favor integrase inhibitors. Such combinations are unlikely to restore Lexiva’s market position.

4. Is there any regulatory consideration for Lexiva?
GSK has not pursued its re-commercialization or new indications recently, mainly due to low market prospects.

5. What is the outlook for GSK regarding Lexiva?
The company maintains limited presence, with no active plans for Lexiva’s development or repositioning.

---

References

1. U.S. Food and Drug Administration. (2003). FDA approval of fosamprenavir.
2. IQVIA. (2023). Global HIV/AIDS medication sales report.
3. GSK. (2012). Patent and exclusivity status for Lexiva.
4. MarketWatch. (2022). Analysis of antiretroviral market share trends.
5. DrugPatentWatch. (2023). Patent expiration and generic competition data.